´ëÇÑÀü¸³¼±ÇÐȸ 2024 KPS Annual Prostate International Meeting : 2024-03-09
±³À°ÀÏÀÚ : 2024-03-09
±³À°Àå¼Ò : ¼¿ï SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽÇ
±³À°ÁÖÁ¦ : 2024 KPS Annual Prostate International Meeting
ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ÇãÀçÀº
¿¬¶ôó : 02-6956-7967
À̸ÞÀÏ : gaonpco@gaonpco.com
±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í - »çÀüµî·Ï: 3¸¸¿ø(Àü¹®ÀÇ, ¿¬±¸¿ø, °£È£»ç) / ¹«·á(Àü°øÀÇ, Çлý) - ÇöÀåµî·Ï: 4¸¸¿ø(Àü¹®ÀÇ, ¿¬±¸¿ø, °£È£»ç) / ¹«·á(Àü°øÀÇ,Çлý) - ¿Ü±¹ÀÎ Âü¿©ÀÚ: ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 09:00~10:00 Prostate cancer, etc Á¶¹®±â(¿øÀڷº´¿ø)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 10:00~10:20 Surgery as radical local treatment (as part of a multimodality approach) Á¶Á¤±â(ÇѾçÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 10:20~10:40 Radiation therapy as radical local treatment (as part of a multimodality approach) ±¸±³Ã¶(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 10:40~11:00 Neoadjuvant Lutetium therapy before RP in high risk PCa patients Nathan LAWRENTSCHUK(University of Melbourne)
Åä·Ð 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:00~11:10 Case-Based Panel Discussion : Presentation Case 1, 2 °µ¿Çõ, ÀÌÁ¾¼ö, ¼¿øÀÍ, ÃÖ¼¼¿µ(ÀÎÇÏÀÇ´ë, ¿¬¼¼ÀÇ´ë, ÀÎÁ¦ÀÇ´ë, Áß¾ÓÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:10~11:25 Coffee Break ()
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:25~11:45 A quest for consensus on focal therapy for prostate cancer Rafael SANCHEZ-SALAS(McGill University in Montreal, Quebec)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:45~12:05 Focal therapy in prostate cancer: Friend or Foe Behfar EHDAIE(Memorial Sloan-Kettering Cancer Center)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 12:05~12:25 How should clinicians confirm if a patient is a candidate for focal therapy and define successful treatment? ÀÌÇйÎ(¼¿ïÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 12:25~12:45 Case-Based Panel Discussion : Presentation Case 1, 2 ÀÌÁ¤¿ì, ½Åµ¿È£, ±èÅÂÈ¿, ¼ÛÇÊÇö(°æÈñÀÇ´ë, °¡Å縯°üµ¿ÀÇ´ë, µ¿¾ÆÀÇ´ë, ¿µ³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 12:45~13:00 Optimal choice in the 1st line mHSPC treatment with apalutamide Á¤°æÁø(°¡ÃµÀÇ´ë)
½Ä»ç 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 13:00~13:45 lunch ()
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 13:45~14:00 Prostate International: past, present, and future Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 14:00~14:20 CRPC: How to best sequence therapies in real life Daniel DANILA(Memorial Sloan-Kettering Cancer Center)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 14:20~14:40 Current role of PSMA-based radioligand therapy for mCRPC ¹ÚÀ翵(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 14:40~15:00 The advent of PARP inhibitors for specific to all-comer application- 1) only for specific patients ¼Û¿Ï(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:00~15:20 The advent of PARP inhibitors for specific to all-comer application- 2) for all-comer patients Á¤À翵(±¹¸³¾Ï¼¾ÅÍ)
ÈÞ½Ä 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:20~15:35 Coffee Break ()
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:35~15:55 Laser and robotics enucleastion ¼Û»óÈÆ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:55~16:15 Vaporization and aqua-ablation ±è¸í(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 16:15~16:35 Should we abandon TURP? Stavros GRAVAS(University of Cyprus )